

26th May 2021

To
Bombay Stock Exchange Limited
Dept. of Corporate Services
Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai :: 400 001
BSE Scrip Code : 533014

To
National Stock Exchange of India Ltd
Listing Dept.
Exchange Plaza, Bandra Kurla Complex
Bandra [E]
Mumbai :: 400 051
NSE Scrip Code :SICAGEN

Dear Sirs,

Sub: Outcome of the Board Meeting

This is to inform that the Board of Directors of the Company at their meeting held today through Video Conferencing, has inter alia considered and approved the audited financial results (both standalone & consolidated results) of the Company for the quarter and year ended 31st March 2021.

The Board has also considered and recommended equity dividend @ 6% (Re. 0.60 per share) for the financial year 2020-21, subject to the approval of shareholders at the ensuing Annual General Meeting.

Pursuant to Regulation 33 of the SEBI (LODR) Regulation 2015, copies of the aforesaid audited financial results together with the reports of auditors are herewith attached.

The proposal for Delisting of equity shares from NSE has been reconsidered.

The above information may kindly be taken on record.

Thanking you,

Yours faithfully,
For Sicagen India Limited


R.Chandrasekar
Whole Time Director
Encls : a/a



Sicagen India Ltd.

Registered & Corporate Office :

4th Floor, Spic House, 88, Mount Road, Guindy, Chennai-600 032, INDIA

Tel : +91 44 4075 4075 | Fax : +91 44 4075 4999 | info@sicagen.com

CIN : L74900TN2004PLC053467 | www.sicagen.com